Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Glioblastoma 12Brain Neoplasms 6Gliosarcoma 5Astrocytoma 4Recurrence 3Oligodendroglioma 3Lymphoma, Follicular 3Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Optic Nerve Glioma 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Glioma 2Diffuse Intrinsic Pontine Glioma 2Central Nervous System Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Cilengitide × Clear all
NCT00082875 2013-06-05

Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Terminated
56 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡